# Aurinia Pharmaceuticals Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Aurinia Pharmaceuticals Inc.).

## Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on autoimmune diseases with high unmet medical need. Its commercial business is centered on LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis. The company also has a development-stage pipeline asset, aritinercept, a dual BAFF/APRIL inhibitor being studied for autoimmune diseases. Aurinia sells directly in the U.S. through specialty pharmacies and a specialty distributor, while also monetizing ex-U.S. markets through its collaboration with Otsuka.

## Products & services

• LUPKYNIS (voclosporin) for lupus nephritis
• U.S. specialty pharmacy distribution of LUPKYNIS
• Otsuka collaboration for ex-U.S. commercialization
• License, collaboration and royalty revenue
• Commercial supply and manufacturing services for Otsuka
• Aritinercept development program for autoimmune diseases

- **Commercial product sales** (91%) — Net sales of LUPKYNIS in the U.S. through specialty pharmacies and a specialty distributor.
- **Collaboration and royalty revenue** (4%) — Milestones, royalties, and licensing income from the Otsuka agreement for ex-U.S. markets.
- **Commercial supply services** (5%) — Manufacturing and supply services provided to Otsuka, including use of the Monoplant capacity.
- **Pipeline development** (0%) — Research and development activity for aritinercept and other autoimmune disease opportunities.

- LUPKYNIS (voclosporin) for active lupus nephritis
- U.S. specialty pharmacy and specialty distributor sales
- Ex-U.S. commercialization through Otsuka partnership
- License, collaboration and royalty revenue from Otsuka
- Commercial supply and manufacturing services for voclosporin
- Aritinercept, a dual BAFF/APRIL inhibitor in development

## Customers

Aurinia’s direct commercial customers are two specialty pharmacies and one specialty distributor in the United States that dispense LUPKYNIS to patients with lupus nephritis. These channel partners matter because they control access, inventory flow, and reimbursement execution for a specialty autoimmune therapy. Outside the U.S., Aurinia’s commercial customer is Otsuka Pharmaceutical, which buys voclosporin inventory and commercializes it across Japan, Europe, the U.K., Switzerland and other territories. The company also receives collaboration and royalty revenue tied to Otsuka’s sales performance, so ex-U.S. demand affects Aurinia indirectly as well as through supply and licensing economics.

- **U.S. specialty pharmacies** (primary) — Buy LUPKYNIS for dispensing to patients with active lupus nephritis and are critical to prescription fulfillment and inventory management.
- **U.S. specialty distributor** (primary) — Purchases and distributes LUPKYNIS in the U.S. channel, supporting access and supply continuity.
- **Otsuka Pharmaceutical** (primary) — Buys voclosporin inventory and commercializes it in Japan, Europe, the U.K., Switzerland and other territories under the collaboration.
- **Patients with lupus nephritis** (primary) — The end users of LUPKYNIS; demand depends on diagnosis, prescribing behavior, and treatment adoption.
- **Autoimmune disease research and development partners** (emerging) — Future partners or collaborators may support development and commercialization of aritinercept or other assets.

- U.S. specialty pharmacies that dispense LUPKYNIS to patients
- U.S. specialty distributor that manages channel access and inventory
- Otsuka Pharmaceutical as ex-U.S. commercialization partner
- Patients with active lupus nephritis as the end market
- Healthcare prescribers treating autoimmune disease and LN
- Payers and reimbursement systems that influence access and uptake

## Geography

Aurinia is incorporated in Alberta, Canada, but its commercial revenue is heavily tied to the United States, where LUPKYNIS is sold through specialty channels. Ex-U.S. business is concentrated in the Otsuka Territories, including Japan, the European Union, the U.K., Switzerland and several smaller markets, where Otsuka commercializes voclosporin. The company also relies on a supply chain that imports certain products into the U.S. primarily from Switzerland, which creates cross-border manufacturing and trade exposure. Geography matters because U.S. policy, tariffs, and import restrictions could affect both Aurinia’s direct supply chain and Otsuka’s downstream commercialization economics.

- Headquartered in Edmonton, Alberta, Canada
- U.S. is the core commercial market for LUPKYNIS
- Otsuka Territories include Japan, EU, U.K., Switzerland and others
- Supply chain imports into the U.S. primarily from Switzerland
- Cross-border commercialization creates tariff and trade-policy exposure
- Ex-U.S. revenue is tied to partner execution rather than direct sales

## Strategy

Aurinia’s near-term strategy is to expand LUPKYNIS penetration in lupus nephritis, which remains the company’s main commercial engine. The company is also using the Otsuka partnership to extend voclosporin reach outside the U.S. while monetizing royalties, milestones, and supply revenue without building a full international sales force. On the operations side, Aurinia is emphasizing supply security and manufacturing efficiency through its dedicated Monoplant arrangement with Lonza. Longer term, the company is advancing aritinercept to build a second autoimmune franchise and reduce dependence on a single product.

- **Expand LUPKYNIS penetration in lupus nephritis** (short-term) — The company is substantially dependent on one commercial product, so deeper adoption is the main driver of growth and cash generation.
- **Strengthen ex-U.S. monetization through Otsuka** (medium-term) — The collaboration provides royalties, milestones, and supply revenue without requiring Aurinia to build direct international infrastructure.
- **Secure manufacturing and supply continuity** (short-term) — Commercial success depends on uninterrupted cGMP-compliant supply from contract manufacturers.
- **Advance aritinercept as a second autoimmune asset** (long-term) — A successful pipeline program could diversify revenue and reduce single-product dependence.

- Grow LUPKYNIS adoption in lupus nephritis
- Use specialty channel execution to deepen U.S. market penetration
- Monetize ex-U.S. markets through the Otsuka collaboration
- Maintain supply security through sole-source manufacturing partners
- Improve production efficiency via the Monoplant arrangement
- Advance aritinercept to diversify the autoimmune pipeline

## Risks

Aurinia is highly exposed to the commercial performance of LUPKYNIS, so slower-than-expected uptake, competitive pressure, or reimbursement challenges could materially affect results. The company also depends on sole-source contract manufacturers and third-party logistics and clinical partners, which creates supply interruption and execution risk. Regulatory and patent protection matter because generic or ANDA challenges could erode exclusivity, while the company is already litigating to defend LUPKYNIS patents. In addition, U.S. trade policy and retaliatory actions in Otsuka Territories could disrupt cross-border supply and commercialization, and the broader autoimmune drug market remains competitive with injectable therapies and investigational BAFF/APRIL competitors.

- **Commercial dependence on LUPKYNIS** [high] — Aurinia’s revenue and cash generation are concentrated in one marketed product, so any slowdown in uptake or access would have an outsized impact.
- **Supply chain interruption** [high] — The company relies on sole-source contract manufacturers and third parties for API, drug product, and distribution services.
- **Patent and generic challenge risk** [high] — ANDA filings and patent litigation could shorten effective exclusivity if claims are invalidated or not infringed.
- **Trade and tariff policy risk** [medium] — The company imports certain products primarily from Switzerland and sells into Otsuka territories, making it vulnerable to policy changes and retaliatory tariffs.
- **Pipeline development risk** [medium] — Aritinercept is still in development and may not achieve clinical or regulatory success.

- Dependence on LUPKYNIS creates concentration risk
- Specialty pharmacy and distributor channel execution can affect sales
- Sole-source manufacturing increases supply interruption risk
- Patent and ANDA litigation could pressure exclusivity
- Competition from injectable LN therapies and off-label regimens
- Trade policy or tariffs could disrupt U.S.-Switzerland supply flows
- Otsuka territory retaliation could hurt ex-U.S. commercialization
- Pipeline risk remains high for aritinercept development

## Accounting

Aurinia’s revenue mix includes point-in-time product sales and collaboration revenue, so quarter-to-quarter results can move materially based on shipment timing and milestone recognition. The company specifically noted that 2024 included a $10.0 million milestone tied to Japanese approval, which makes collaboration revenue less recurring and more volatile than product sales. Cost of revenue includes manufacturing, shipping, storage and distribution, plus amortization of the Monoplant finance lease right-of-use asset, so production volume and facility utilization affect gross margin. Investors should also watch estimates around inventory, channel sales to specialty pharmacies, and lease accounting for the dedicated manufacturing facility, because these judgments can materially affect reported earnings and cash flow comparability.

- **Revenue recognition for product sales and collaboration revenue** — Can cause large quarter-to-quarter swings in revenue mix
- **Milestone revenue recognition** — Makes year-over-year collaboration revenue less predictable
- **Monoplant lease accounting** — Impacts gross margin and operating leverage
- **Inventory and channel estimates** — Can affect revenue timing and reserve estimates

- Net product sales are recognized when specialty pharmacies or Otsuka take control
- Collaboration revenue can include milestones and royalties, creating volatility
- Quarterly results can swing with shipment timing and inventory movements
- Monoplant finance lease accounting affects cost of revenue through amortization
- Manufacturing and distribution costs influence gross margin on LUPKYNIS
- Inventory and channel estimates matter for specialty pharmacy sales

---

*Last updated: 2026-08-11T04:46:21.727781+00:00*